← Back to Search

Cardiac MRI for Tricuspid Regurgitation

N/A
Recruiting
Led By Mohamad Alkhouli, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial assesses the severity of tricuspid regurgitation with cardiac MRI.

Who is the study for?
This trial is for individuals with moderate or severe tricuspid regurgitation, which is when the heart's tricuspid valve doesn't close properly. Participants must not have a pacemaker/defibrillator that interferes with MRI, any prior tricuspid valve replacements, planned surgery on the tricuspid valve, or primary liver disease.Check my eligibility
What is being tested?
The study aims to evaluate how well cardiac magnetic resonance imaging (MRI) can determine the severity of tricuspid regurgitation in patients' hearts.See study design
What are the potential side effects?
Cardiac MRI is generally safe; however, some may experience discomfort from lying still during the procedure. There are no significant side effects associated directly with this non-invasive imaging technique.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Severity of tricuspid regurgitation by cardiac magnetic resonance imaging
Secondary outcome measures
Correlation between severity of Tricuspid regurgitation by cardiac magnetic resonance imaging vs. elastography

Trial Design

1Treatment groups
Experimental Treatment
Group I: Moderate or severe tricuspid regurgitationExperimental Treatment1 Intervention
40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac Magnetic Resonance
2018
N/A
~150

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,757,971 Total Patients Enrolled
Mohamad Alkhouli, MDPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current cohort size for this research project?

"Indeed, the clinicaltrial.gov listings indicate that this trial is currently enrolling patients. This experiment was initially posted on January 14th 2022 and recently updated on September 27th 2022. 60 participants are required at one medical centre to complete the study."

Answered by AI

Is it possible to gain admittance into this medical investigation if one is an octogenarian?

"To be considered, applicants must have attained the age of majority and yet to reach their centenary."

Answered by AI

Are there currently any slots available for enrolment in this trial?

"Affirmative. The online repository of clinical trials data states that this experiment, which was posted for the first time on January 14th 2022, is actively recruiting participants. Approximately 60 individuals are needed from 1 medical centre to take part in this trial."

Answered by AI

Is there an opportunity to participate in this medical research?

"This clinical trial is recruiting up to 60 individuals aged 18-99 with moderate or higher levels of tricuspid valve regurgitation."

Answered by AI
~25 spots leftby Mar 2025